SYNERA Drug Patent Profile
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
When do Synera patents expire, and what generic alternatives are available?
Synera is a drug marketed by Galen Specialty and is included in one NDA.
The generic ingredient in SYNERA is lidocaine; tetracaine. There are twenty-nine drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the lidocaine; tetracaine profile page.
Summary for SYNERA
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Clinical Trials: | 21 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for SYNERA |
| What excipients (inactive ingredients) are in SYNERA? | SYNERA excipients list |
| DailyMed Link: | SYNERA at DailyMed |
Recent Clinical Trials for SYNERA
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Boston Children’s Hospital | N/A |
| Boston Children's Hospital | N/A |
| Linde AG | N/A |
Anatomical Therapeutic Chemical (ATC) Classes for SYNERA
US Patents and Regulatory Information for SYNERA
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Galen Specialty | SYNERA | lidocaine; tetracaine | PATCH;TOPICAL | 021623-001 | Jun 23, 2005 | DISCN | Yes | No | See Plans and Pricing | See Plans and Pricing | See Plans and Pricing | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for SYNERA
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Galen Specialty | SYNERA | lidocaine; tetracaine | PATCH;TOPICAL | 021623-001 | Jun 23, 2005 | See Plans and Pricing | See Plans and Pricing |
| Galen Specialty | SYNERA | lidocaine; tetracaine | PATCH;TOPICAL | 021623-001 | Jun 23, 2005 | See Plans and Pricing | See Plans and Pricing |
| Galen Specialty | SYNERA | lidocaine; tetracaine | PATCH;TOPICAL | 021623-001 | Jun 23, 2005 | See Plans and Pricing | See Plans and Pricing |
| Galen Specialty | SYNERA | lidocaine; tetracaine | PATCH;TOPICAL | 021623-001 | Jun 23, 2005 | See Plans and Pricing | See Plans and Pricing |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for SYNERA
See the table below for patents covering SYNERA around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Germany | 69930401 | See Plans and Pricing | |
| World Intellectual Property Organization (WIPO) | 0103625 | See Plans and Pricing | |
| China | 1200017 | See Plans and Pricing | |
| Canada | 2450366 | See Plans and Pricing | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2023 - 2024
NCE-1 Patent Challenge Dates 2023 - 2024
ClinicalTrialExchange - Connecting volunteers and trials
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2023, www.DrugPatentWatch.com.
Follow DrugPatentWatch:
